Identification of Drugs Inducing Phospholipidosis by Novel in vitro Data

Drug‐induced phospholipidosis (PLD) is a lysosomal storage disorder characterized by the accumulation of phospholipids within the lysosome. This adverse drug effect can occur in various tissues and is suspected to impact cellular viability. Therefore, it is important to test chemical compounds for their potential to induce PLD during the drug design process. PLD has been reported to be a side effect of many commonly used drugs, especially those with cationic amphiphilic properties. To predict drug‐induced PLD in silico, we established a high‐throughput cell‐culture‐based method to quantitatively determine the induction of PLD by chemical compounds. Using this assay, we tested 297 drug‐like compounds at two different concentrations (2.5 μM and 5.0 μM). We were able to identify 28 previously unknown PLD‐inducing agents. Furthermore, our experimental results enabled the development of a binary classification model to predict PLD‐inducing agents based on their molecular properties. This random forest prediction system yields a bootstrapped validated accuracy of 86 %. PLD‐inducing agents overlap with those that target similar biological processes; a high degree of concordance with PLD‐inducing agents was identified for cationic amphiphilic compounds, small molecules that inhibit acid sphingomyelinase, compounds that cross the blood–brain barrier, and compounds that violate Lipinski’s rule of five. Furthermore, we were able to show that PLD‐inducing compounds applied in combination additively induce PLD.

[1]  C. Lunte,et al.  Distribution of Tacrine Across the Blood–Brain Barrier in Awake, Freely Moving Rats Using in Vivo Microdialysis Sampling , 2004, Pharmaceutical Research.

[2]  D. Ortwine,et al.  Distribution of tacrine and metabolites in rat brain and plasma after single- and multiple-dose regimens. Evidence for accumulation of tacrine in brain tissue. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[3]  W. Daniel,et al.  Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping , 2001, British journal of pharmacology.

[4]  R. Lüllmann-Rauch,et al.  Lipidosis induced by amphiphilic cationic drugs. , 1978, Biochemical pharmacology.

[5]  Roger G. Ulrich,et al.  An in Vitro Fluorescence Assay for the Detection of Drug-Induced Cytoplasmic Lamellar Bodies , 1991 .

[6]  B. Kishore,et al.  Modulation of the in vitro activity of lysosomal phospholipase A1 by membrane lipids. , 2005, Chemistry and physics of lipids.

[7]  Gus R Rosania,et al.  Effect of Phospholipidosis on the Cellular Pharmacokinetics of Chloroquine , 2011, Journal of Pharmacology and Experimental Therapeutics.

[8]  J. Seki,et al.  Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes. , 2008, Biochemical and biophysical research communications.

[9]  G. Verheyen,et al.  Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.

[10]  R. Anderson,et al.  Carrier concentration model for n‐type silicon at low temperatures , 1989 .

[11]  U. Leli,et al.  Modifications of phospholipid metabolism induced by chlorpromazine, desmethylimipramine and propranolol in C6 glioma cells. , 1987, Biochemical pharmacology.

[12]  S. Kacew Cationic amphiphilic drug-induced renal cortical lysosomal phospholipidosis: an in vivo comparative study with gentamicin and chlorphentermine. , 1987, Toxicology and applied pharmacology.

[13]  Mesens Natalie,et al.  A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[14]  J. Kornhuber,et al.  Identification of Novel Functional Inhibitors of Acid Sphingomyelinase , 2011, PloS one.

[15]  W. Risau Differentiation of endothelium , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  R. Ulrich,et al.  Drug-induced phospholipidosis: issues and future directions , 2006, Expert opinion on drug safety.

[17]  Klaus R. Liedl,et al.  Qualitative prediction of blood–brain barrier permeability on a large and refined dataset , 2011, J. Comput. Aided Mol. Des..

[18]  J. B. Hutchins,et al.  Amiodarone-induced lymphocyte toxicity and mitochondrial function. , 1996, Journal of cardiovascular pharmacology.

[19]  Jasper Dingemanse,et al.  Phospholipidosis in healthy subjects participating in clinical studies: ultrastructural findings in white blood cells. , 2010, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[20]  A. Ratcliffe,et al.  Medicinal chemistry strategies to minimize phospholipidosis. , 2009, Current medicinal chemistry.

[21]  D. Myszka,et al.  Probing the mechanism of drug/lipid membrane interactions using Biacore. , 2004, Analytical biochemistry.

[22]  G. Rosania,et al.  Molecular imaging of intracellular drug-membrane aggregate formation. , 2011, Molecular pharmaceutics.

[23]  Mark J. Reasor,et al.  Drug-Induced Phospholipidosis: Are There Functional Consequences? , 2001, Experimental biology and medicine.

[24]  M. J. Hazen,et al.  Cellular responses associated with dibucaine-induced phospholipidosis. , 2011, Chemical research in toxicology.

[25]  Y-K Lee,et al.  Validation of an in vitro screen for phospholipidosis using a high-content biology platform , 2006, Cell Biology and Toxicology.

[26]  Thomas Kolter,et al.  Principles of lysosomal membrane degradation: Cellular topology and biochemistry of lysosomal lipid degradation. , 2009, Biochimica et biophysica acta.

[27]  M. Samanta,et al.  Significant delivery of tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer's disease , 2009, Journal of Neuroscience Methods.

[28]  K. Hostetler,et al.  Mechanism of cationic amphiphilic drug inhibition of purified lysosomal phospholipase A1. , 1985, Biochemistry.

[29]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[30]  B Müller-Oerlinghausen,et al.  The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry , 2004, Pharmacopsychiatry.

[31]  Matthew J Sykes,et al.  Characterisation of the Binding of Cationic Amphiphilic Drugs to Phospholipid Bilayers Using Surface Plasmon Resonance , 2007, ChemMedChem.

[32]  Carl Alden,et al.  Biomarkers to monitor drug-induced phospholipidosis. , 2007, Toxicology and applied pharmacology.

[33]  Santiago Vilar,et al.  Prediction of passive blood-brain partitioning: straightforward and effective classification models based on in silico derived physicochemical descriptors. , 2010, Journal of molecular graphics & modelling.

[34]  J. Kornhuber,et al.  Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A Novel Pharmacological Group of Drugs with Broad Clinical Applications , 2010, Cellular Physiology and Biochemistry.

[35]  M. Hollinger Drug-Induced Lung Toxicity , 1993 .

[36]  David Furcy,et al.  Limited Discrepancy Beam Search , 2005, IJCAI.

[37]  Nigel Greene,et al.  Evaluation of a Published in Silico Model and Construction of a Novel Bayesian Model for Predicting Phospholipidosis Inducing Potential , 2007, J. Chem. Inf. Model..

[38]  R. Baselt,et al.  Therapeutic and toxic concentrations of more than 100 toxicologically significant drugs in blood, plasma, or serum: a tabulation. , 1975, Clinical chemistry.

[39]  K. Sandhoff,et al.  The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. , 1994, Biological chemistry Hoppe-Seyler.

[40]  K. Sandhoff,et al.  Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. , 2005, Annual review of cell and developmental biology.

[41]  Nuria E. Campillo,et al.  Artificial Neural Networks in ADMET Modeling: Prediction of Blood–Brain Barrier Permeation , 2008 .

[42]  K. Sandhoff Membrane lipids and degenerative lysosomal storage disorders , 2009 .

[43]  Ovidiu Ivanciuc,et al.  Weka machine learning for predicting the phospholipidosis inducing potential. , 2008, Current topics in medicinal chemistry.

[44]  U. Kodavanti,et al.  Cationic amphiphilic drugs and phospholipid storage disorder. , 1990, Pharmacological reviews.

[45]  K. Abromeit Music Received , 2023, Notes.

[46]  Robert C. Glen,et al.  Predicting Phospholipidosis Using Machine Learning , 2010, Molecular pharmaceutics.

[47]  K. Larntz Small-Sample Comparisons of Exact Levels for Chi-Squared Goodness-of-Fit Statistics , 1978 .

[48]  R. Austin,et al.  Partitioning of ionizing molecules between aqueous buffers and phospholipid vesicles. , 1995, Journal of pharmaceutical sciences.

[49]  Mark E Cartwright,et al.  Phospholipidosis in Neurons Caused by Posaconazole, without Evidence for Functional Neurologic Effects , 2009, Toxicologic pathology.

[50]  P. Ros,et al.  Fluoxetine hydrochloride (Prozac)-induced pulmonary disease. , 1995, Chest.

[51]  R. Lüllmann-Rauch,et al.  Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine. , 1975, CRC critical reviews in toxicology.

[52]  J. Falgueyret,et al.  Quantitation of the lysosomotropic character of cationic amphiphilic drugs using the fluorescent basic amine Red DND-99. , 2004, Analytical biochemistry.

[53]  A. Abe,et al.  The role of negatively charged lipids in lysosomal phospholipase A2 function , 2009, Journal of Lipid Research.

[54]  D. Dhumeaux,et al.  Amiodarone‐induced hepatic phospholipidosis: A morphological alteration independent of pseudoalcoholic liver disease , 1988, Hepatology.

[55]  F. Young Biochemistry , 1955, The Indian Medical Gazette.

[56]  D. Morton,et al.  A Strategy for Risk Management of Drug-Induced Phospholipidosis , 2009, Toxicologic pathology.

[57]  S. Sutrina,et al.  Effects of lysosomotropic agents on lipogenesis. , 1986, Archives of biochemistry and biophysics.

[58]  M McCarthy,et al.  Hepatology , 1999, Rapid Medicine.

[59]  E. Downar,et al.  Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. , 1984, Gastroenterology.

[60]  Utkan Demirci,et al.  Rapid automated cell quantification on HIV microfluidic devices. , 2009, Lab on a chip.

[61]  P. Kinnunen,et al.  Screening for the Drug–Phospholipid Interaction: Correlation to Phospholipidosis , 2009, ChemMedChem.

[62]  D. Monteith,et al.  In vitro assays and biomarkers for drug-induced phospholipidosis , 2006, Expert opinion on drug metabolism & toxicology.

[63]  Hao Zhu,et al.  Estimation of the Aqueous Solubility of Organic Molecules by the Group Contribution Approach , 2001, J. Chem. Inf. Comput. Sci..

[64]  Katarzyna R Przybylak,et al.  In Silico Studies of the Relationship Between Chemical Structure and Drug Induced Phospholipidosis , 2011, Molecular informatics.

[65]  S. Kharb Toxicology , 1936 .

[66]  L. Lehman-Mckeeman,et al.  Evaluation and validation of multiple cell lines and primary mouse macrophages to predict phospholipidosis potential. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[67]  P. Seeman,et al.  Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.

[68]  Akira Abe,et al.  A role for lysosomal phospholipase A2 in drug induced phospholipidosis. , 2007, Drug metabolism letters.

[69]  W H Halliwell,et al.  Cationic Amphiphilic Drug-Induced Phospholipidosis , 1997, Toxicologic pathology.

[70]  T M Dwyer,et al.  Types of interaction of amphiphilic drugs with phospholipid vesicles. , 1988, The Journal of pharmacology and experimental therapeutics.

[71]  Toru Yamada,et al.  Identification of a novel set of biomarkers for evaluating phospholipidosis-inducing potential of compounds using rat liver microarray data measured 24-h after single dose administration. , 2012, Toxicology.

[72]  K. von Figura,et al.  Biogenesis of lysosomal membranes , 1994, FEBS letters.

[73]  F. Hsieh,et al.  Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities , 2010, Expert opinion on drug metabolism & toxicology.

[74]  B. Lord Controls on the cell cycle. , 1986, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[75]  Xianlin Han,et al.  Lysosomal Phospholipase A2 and Phospholipidosis , 2006, Molecular and Cellular Biology.

[76]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[77]  Yi Xie,et al.  Antidepressant-induced lipidosis with special reference to tricyclic compounds , 2000, Progress in Neurobiology.

[78]  Takashi Nonoyama,et al.  Drug-induced Phospholipidosis : Pathological Aspects and Its Prediction , 2008 .

[79]  Jan Kelder,et al.  Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. , 2004, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[80]  H. Goldberg,et al.  Increased hepatic density and phospholipidosis due to amiodarone. , 1985, AJR. American journal of roentgenology.

[81]  Thomas Singer,et al.  In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. , 2012, Journal of medicinal chemistry.

[82]  S. Uhlig,et al.  The role of sphingolipids in respiratory disease , 2011, Therapeutic advances in respiratory disease.

[83]  Randy M. Perse,et al.  Histopathologic analysis of suspected amiodarone hepatotoxicity. , 1990, Human pathology.

[84]  Yukihiro Kuroda,et al.  Prediction of phospholipidosis-inducing potential of drugs by in vitro biochemical and physicochemical assays followed by multivariate analysis. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.

[85]  Jianling Wang,et al.  Predicting phospholipidosis: a fluorescence noncell based in vitro assay for the determination of drug-phospholipid complex formation in early drug discovery. , 2011, Analytical chemistry.

[86]  J Kapuscinski,et al.  DAPI: a DNA-specific fluorescent probe. , 1995, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[87]  M. Wehling,et al.  The binding of drugs to different polar lipids in vitro. , 1979, Biochemical pharmacology.

[88]  F. Crivellente,et al.  A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development , 2003, Cell Biology and Toxicology.

[89]  P. Kinnunen,et al.  Assessment of drug-lipid complex formation by a high-throughput Langmuir-balance and correlation to phospholipidosis. , 2008, Journal of medicinal chemistry.

[90]  C. Masimirembwa,et al.  Lysosomal trapping of amodiaquine: impact on transport across intestinal epithelia models , 2008, Biopharmaceutics & drug disposition.

[91]  J. Corradi,et al.  Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. , 2010, Chemical research in toxicology.

[92]  Kenji Takami,et al.  A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[93]  Naomi L Kruhlak,et al.  Development of a Phospholipidosis Database and Predictive Quantitative Structure-Activity Relationship (QSAR) Models , 2008, Toxicology mechanisms and methods.

[94]  Johannes Kornhuber,et al.  Quantitative modeling of selective lysosomal targeting for drug design , 2008, European Biophysics Journal.

[95]  W. Daniel Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[96]  A. Gonzales,et al.  Induction of Apoptosis by Cationic Amphiphilic Drugs Amiodarone and Imipramine , 2005, Drug and chemical toxicology.

[97]  K. Sandhoff,et al.  Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine , 2004, FEBS letters.

[98]  Prabha Garg,et al.  In Silico Prediction of Blood Brain Barrier Permeability: An Artificial Neural Network Model , 2006, J. Chem. Inf. Model..

[99]  J. Pauluhn Inhaled cationic amphiphilic drug-induced pulmonary phospholipidosis in rats and dogs: time-course and dose-response of biomarkers of exposure and effect. , 2005, Toxicology.

[100]  Byung-Hoon Lee,et al.  In vitro validation of drug-induced phospholipidosis. , 2012, The Journal of toxicological sciences.

[101]  J. Kornhuber,et al.  Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? , 1995, Journal of neural transmission. Supplementum.

[102]  Z Hruban,et al.  Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. , 1984, Environmental health perspectives.

[103]  Tsuyoshi Harada,et al.  Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[104]  W. Schoonen,et al.  High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[105]  Michael S Roberts,et al.  Ion-Trapping, Microsomal Binding, and Unbound Drug Distribution in the Hepatic Retention of Basic Drugs , 2004, Journal of Pharmacology and Experimental Therapeutics.

[106]  Guoliang Zhang,et al.  Evaluation of amiodarone-induced phospholipidosis by in vitro system of 3D cultured rat hepatocytes in gel entrapment , 2010 .

[107]  Elazer R. Edelman,et al.  Adv. Drug Delivery Rev. , 1997 .

[108]  A. Horinouchi,et al.  Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats , 2009, Toxicology mechanisms and methods.